No Benefit From Defibrillation Threshold Testing in the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial)
Joseph A. Blatt, MD*,*,
Jeanne E. Poole, MD*,
George W. Johnson, BSEE ,
David J. Callans, MD ,
Merritt H. Raitt, MD ,
Ramakota K. Reddy, MD||,
Francis E. Marchlinski, MD ,
Raymond Yee, MD¶,
Thomas Guarnieri, MD#,
Mario Talajic, MD**,
David J. Wilber, MD ,
Jill Anderson, RN ,
Kiyon Chung, MD, MPH ,
Wai Shun Wong, MD ,
Daniel B. Mark, MD||||,
Kerry L. Lee, PhD||||,
Gust H. Bardy, MD*, for the SCD-HeFT Investigators
* University of Washington, Seattle, Washington
Seattle Institute for Cardiac Research, Seattle, Washington
The University of Pennsylvania, Philadelphia, Pennsylvania
Portland Veterans Affairs Medical Center, Portland, Oregon
|| Oregon Cardiology, P.C., Eugene, Oregon
¶ University of Western Ontario, London, Ontario, Canada
# John Hopkins University, Baltimore, Maryland
** Montreal Heart Institute, Montreal, Quebec, Canada
 Loyola University Health System, Maywood, Illinois
 The Everett Clinic, Everett, Washington
 University of Michigan, Ann Arbor, Michigan
|||| Duke University School of Medicine, Durham, North Carolina.

View larger version (14K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 2 Kaplan-Meier Survival Curves
Curves show no difference in all-cause mortality when patients with an ICD were divided by high-DFT and low-DFT groups (hazard ratio for DFT >10: 1.19; 95% confidence interval: 0.72 to 1.58; p = 0.41). Abbreviations as in Figure 1.
|
|
|